22 avril 2026
As China solidifies its position as a global innovation and manufacturing powerhouse, multinational corporations (MNCs) are moving beyond basic market adaptation. The new imperative is “deep localization”, a fundamental strategic integration of research and development (R&D), intellectual property (IP) management, legal structuring, and technology capitalization into China’s unique industrial and regulatory ecosystem. This approach is no longer optional for market access; it is essential for capturing local opportunities, leveraging China’s innovation velocity, and building a durable competitive edge. Regulatory pressure, in particular China’s evolving local content requirements and government procurement rules, adds a further and increasingly urgent dimension to this imperative. This article explores the core dimensions of this strategy: the regulatory and market access drivers compelling localization, localized R&D as its operational foundation, a restructured IP and legal framework as its core, and technology capitalization, including alternative structuring options, as its logical extension.
The strategic case for deep localization does not arise in a regulatory vacuum. Beyond market dynamics and innovation considerations, foreign investors operating in China face a growing body of regulatory and procurement-related requirements that make localization not merely attractive, but in many instances economically necessary.
A significant regulatory development took effect on 1 January 2026: the State Council’s Notice on Implementing Domestic Product Standards and Related Policies in Government Procurement (Guobanfa [2025] No. 34, the “Notice”), issued on 30 September 2025. The Notice introduces a 20% price evaluation advantage for products manufactured or substantially transformed within China in competitive government procurement tenders. In practical terms, a “Made in China” product can be priced significantly higher than a foreign-made equivalent and still win a bid on evaluated price. The policy applies equally to state-owned enterprises, private enterprises, and foreign-invested enterprises (FIEs), meaning MNCs that manufacture locally can benefit just as much as domestic competitors.
Crucially, the Notice also provides the first clear statutory definition of what constitutes a “domestic product.” To qualify, a product must meet three cumulative criteria: (i) it must be manufactured or substantially transformed within China’s customs territory, with genuine manufacturing activity required, as mere assembly, packaging, labeling, or branding does not suffice; (ii) the cost of components produced within China must meet a minimum proportion of total product cost, with specific thresholds to be determined by the Ministry of Finance over a phased period of up to five years; and (iii) for products involving advanced technologies or national security concerns, key components and critical manufacturing processes must be performed in China. During the transition period, products meeting criterion (i) will generally be treated as domestic pending finalization of the remaining thresholds.
Foreign investors sometimes question whether China’s local content preferences in government procurement are compatible with its WTO commitments. The answer requires an important distinction. While China acceded to the WTO in 2001 and is bound by core WTO agreements, including TRIPS and the Agreement on Technical Barriers to Trade, it has notably not acceded to the WTO Agreement on Government Procurement (GPA). The GPA is a plurilateral agreement, binding only on those WTO members that have specifically signed up to it, and China, despite years of observer-status negotiations, remains outside its scope. As a consequence, China is under no WTO obligation to open its government procurement market to non-discriminatory foreign participation, and the domestic preference rules introduced by the Notice are not in themselves a violation of China’s international trade commitments. Foreign companies must therefore treat these rules not as a temporary or challengeable anomaly, but as a structural feature of the Chinese market that demands a strategic response.
The formal regulatory framework described above sits alongside a longstanding and well-documented informal “Buy China” preference that has historically operated independently of any written rules. The European Union Chamber of Commerce in China (EUCCC) has consistently reported that foreign companies, including those that develop and manufacture products entirely within China, frequently find their products excluded from public procurement processes without clear legal basis. Prior to the Notice, the absence of any statutory definition of “made in China” left procurement bodies with wide discretion to exclude foreign-branded products irrespective of their actual local content. The Notice goes some way towards addressing this ambiguity, but the transition period means that uncertainty will persist for several years.
In parallel, China’s volume-based procurement (VBP) system, particularly prominent in the healthcare and medical devices sector, creates additional competitive pressure. VBP processes require bidders to supply large quantities of products at heavily discounted rates, compressing margins and imposing demanding delivery schedules. To remain competitive, foreign companies have been compelled to restructure supply chains and increase local investments, often with no assurance of continued access.
For MNCs pursuing deep localization, establishing R&D capabilities in China is the essential first step. The motivation has evolved far beyond simply adapting global products for the local market. Today, China's unique market dynamics, comprehensive industrial ecosystem, and remarkable innovation efficiency are primary drivers for embedding R&D resources deeply within the country.China's sheer market scale is a compelling factor. For instance, the automotive sector illustrates a leading trend of integrating China-based R&D into global innovation portfolios. According to the China Passenger Car Association (CPCA), China accounts for 35.6% of global auto sales, with new energy vehicle (NEV) penetration exceeding 54% in 2025. Catering to this massive and uniquely demanding consumer base makes local R&D a vital source of global product innovation.Furthermore, "China speed"—the accelerated pace of development and iteration—offers a distinct competitive advantage. This efficiency is fueled by a complete industrial supply chain, advanced infrastructure (like extensive 5G and vehicle-to-everything (V2X) networks), and a deep pool of technical talent in high-demand fields such as software and algorithms. This combination creates an innovation ecosystem that is difficult to replicate elsewhere, making local R&D not just beneficial, but strategically critical.
The logical consequence of R&D localization is the need to restructure how intellectual property is owned and managed. The traditional centralized model, where global headquarters retains ownership of all IP and merely licenses it to Chinese subsidiaries, is increasingly ill-suited to the realities of local innovation.
| Feature | Traditional Centralized IP Model |
Restructured Decentralized IP Model |
|---|---|---|
| Background IP Ownership | Held by global headquarters. | Held by global headquarters. |
| Foreground IP Ownership (from local R&D) | Held by global headquarters. | Held by the Chinese subsidiary. |
| Subsidiary Role | Licensee, paying fees to headquarters. | Owner of its own innovations; manages its IP portfolio. |
This shift towards IP localization offers significant strategic advantages, but also introduces considerable risks that require careful navigation.
Long-term Strategic Drift: Excessive IP autonomy could make the subsidiary overly independent, potentially leading to strategic misalignment or internal competition with the global group.
To balance these opportunities and risks, a phased and strategic approach is crucial. A hybrid IP model is often the most pragmatic solution. This might involve exclusive cross-licensing agreements between headquarters and the subsidiary, or joint ownership of foreground IP, with robust legal contracts clearly defining rights, usage scopes, and profit-sharing mechanisms. Implementation can be phased, starting with less critical technologies for local ownership and gradually expanding as local capabilities and the regulatory environment mature. This approach allows MNCs to leverage local resources and opportunities while maintaining core strategic control.
Deep localization culminates in the capitalization of technology, with "IP contribution"—using IP rights as capital investment in a Chinese entity—being a primary mechanism. China’s revised Company Law (2023) provides a clear legal foundation for this, stipulating that IP can be used as non-monetary capital if it is monetarily valuable, legally transferable, and has clearly established ownership or usage rights. Notably, the 2013 revision removed the historical cap (上限) on the proportion of IP contribution, granting significant autonomy, although MNCs must still verify any specific local provincial requirements.
While IP ownership contribution as described above is an established tool, a parallel trend has emerged: many foreign investors are increasingly seeking to limit their cash exposure in China, driven by geopolitical uncertainty, concerns about capital repatriation, and a generally more cautious investment appetite, by contributing a technology license as their capital contribution to a new FIE, rather than making a traditional cash investment. From a legal structuring perspective, however, this approach raises issues that deserve careful consideration.
Under the 2023 Company Law (effective 1 July 2024), non-monetary assets eligible for capital contribution include intellectual property rights, provided they are capable of monetary valuation and are legally transferable (Article 48). The 2023 Company Law also removed the previous 30% minimum cash contribution requirement, allowing registered capital to be contributed entirely in non-monetary form. The implementation measures issued on 20 December 2024 confirmed that this includes intangible assets such as IP rights. The contribution of a technology license, as a use right distinct from full IP ownership, is therefore legally permissible under PRC law, subject to proper valuation and registration formalities.
Where commercially feasible, particularly in a joint venture (JV) context, the legally cleaner and more advisable structure is typically for the foreign investor to contribute cash as registered capital, and for the JV to then use that cash to pay a technology license fee to the foreign parent under a separate technology license agreement. This fee can be structured as a one-off upfront lump sum, ongoing running royalties, or a combination of both. This approach offers several important advantages: it avoids the mandatory professional valuation process required for non-monetary IP contributions (which is both costly and legally high-risk, as described above); it preserves full IP ownership within the foreign group, thereby protecting against technology leakage and ensuring the parent retains undiminished control over its technology portfolio; and it creates a legitimate, commercially recognized mechanism for repatriating value through royalty streams, which are generally subject to a 10% withholding tax in China (or a reduced rate under applicable double tax treaties).
There is an inherent short-term cash flow impact under this model: the investor contributes cash which is then paid out as a license fee before operating returns are generated. However, once royalty payments are established and flowing, this structure typically produces a more efficient and predictable capital repatriation profile than dividend distributions, which are subject to additional procedural requirements.
Where the direct cash contribution route is not commercially viable and investors wish instead to contribute a technology license directly as registered capital, this gives rise to a genuinely complex legal question under PRC law. A technology license, by its nature, is a use right (使用权), granting access to technology for a defined purpose and duration without transferring ownership. Standard licensing arrangements under PRC contract law and the Technology Import and Export Administration Regulations (TIEAR) typically include termination provisions, creating a structural tension: if the licensor can terminate the license, what happens to the registered capital it was meant to represent?
The answer under PRC company law is that, once a license is formally contributed as registered capital and registered with the relevant authorities, the licensor’s ordinary right of termination sits in fundamental tension with the capital contribution framework. This point is not expressly addressed in the 2023 Company Law or its implementing measures, but the prevailing legal analysis is that unilaterally revoking a license that constitutes registered capital would amount to an illegal withdrawal of capital, which is prohibited under Article 53 of the 2023 Company Law and would expose the contributing shareholder to civil and potentially administrative liability. In effect, the act of contribution is widely understood to transform the license from a revocable contractual arrangement into a quasi-permanent equity asset for the duration of the company’s existence. While this analysis has not yet been conclusively tested before PRC courts in the specific context of contributed licenses, it flows logically from the capital maintenance principle that underpins Chinese company law, and investors should proceed on the assumption that termination of a contributed license would be treated as an impermissible capital withdrawal.
This creates important practical implications for the drafting of both the license agreement and the company’s constitutional documents. The Articles of Association should clearly specify whether the capital contribution is of IP ownership or merely usage rights. The license agreement should be drafted with the irrevocability of the contribution in mind: standard termination clauses will need to be absent or carefully circumscribed to avoid conflicting with the capital contribution framework. The mandatory valuation obligation also remains fully applicable. This means in practice that the contributed usage rights must be independently appraised by a qualified institution, and the contributor bears the statutory liability regime for defective appraisals.
From an IP protection perspective, the license-as-contribution model has a clear advantage over outright IP ownership transfer: title remains with the foreign parent at all times, substantially reducing the risk of technology leakage in the event of a JV breakdown or forced divestment. However, the irrevocability of the contributed license means that the foreign investor loses practical control over the technology for as long as the company remains in existence, which in certain adverse scenarios can approach the risks of an outright ownership transfer. Investors should therefore ensure that the JV agreement contains robust exit mechanisms, including dissolution triggers, that would release the license upon termination of the venture, and should take legal advice on whether those mechanisms are enforceable under both PRC law and the governing law of the JV agreement.
In summary, while the technology license contribution model is a legally recognized and increasingly considered tool for investors seeking to limit cash exposure in China, it should not be adopted without thorough legal structuring.
Deep localization in China is a strategic evolution demanding balance: balancing decentralized R&D and IP authority with global corporate oversight, and balancing the pursuit of local market opportunities with the mitigation of IP and regulatory risks. Its success lies in integrating local innovation, IP strategy, legal compliance, and technology capitalization into a unified global framework.
This requires MNCs to move beyond a traditional "center-periphery" mindset and instead treat China as an equal and integral innovation partner. By building a localized R&D, IP, and capital structure that aligns with global strategy, MNCs can harness China's speed, industrial synergy, and market scale not just for local success, but to drive their worldwide growth and achieve sustainable development in one of the world's most dynamic economies.
---
Footnotes:
[1]: CPCA data, Feb 2026
[2]: CPCA data, Jan 2026
par Chao Xuan
Our China team looks at the impact of China's latest data security law on international businesses
par Julian Sun et Chao Xuan